PHILADELPHIA--(BUSINESS WIRE)--Jan. 17, 2006--AVAX Technologies, Inc. (OTCMarket: AVXT.OB) today announces that enrollment is commencing for its Phase I/II study in patients with Non-Small Cell Lung Cancer. The study will enroll patients with surgically resectable non-small cell lung cancer for adjuvant treatment with AVAX’s AC Vaccine technology. The vaccine is composed of tumor cells obtained from each patient’s tumor that are modified with the hapten, dinitrophenyl (DNP). Endpoints of the study include safety and a measure of each patient’s immune response to their cancer after vaccination using a delayed-type hypersensitivity (DTH) test.
